Do you have Atopic Dermatitis?
Atopic dermatitis (AD), the most common form of eczema, is a chronic inflammatory skin disorder that affects individuals of all ages, ethnicities, and geographic regions worldwide.
We are currently recruiting participants aged 18 to 74 years with moderate to severe Atopic Dermatitis (Eczema) to take part in a research study.
Compensation for time and travel may be available. There will be no cost to you for being considered or for participating in this study, and you will be provided with all study medication, examinations, and medical care related to the study.
Join the trial to contribute to the research of this treatment for AD and potentially benefit from its effects.
Visits
Total
Length
Study Length
Total
Up to 20 visits over approximately 16 months
Length
2.5 to 4 hours
Study Length
Up to 5 weeks of screening period, up to 48 weeks of treatment and approximately 16 weeks of follow up period, with the possibility to be invited to participate in a separate long-term extension study
Summary
This study is being done to test how safe is the study drug and how well it relives the signs and symptoms of your atopic dermatitis. The study drug, which is called IMG-007, is given as an injection under the skin by a healthcare professional.
